Halozyme Therapeutics (HALO) Tops Q2 EPS by 6c, Offers Guidance
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $39.43 +1.18%
EPS Growth %: +48.9%
Financial Fact:
Revenues under collaborative agreements: 5.49M
Today's EPS Names:
CP, RUSHA, SEIC, More
EPS Growth %: +48.9%
Financial Fact:
Revenues under collaborative agreements: 5.49M
Today's EPS Names:
CP, RUSHA, SEIC, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of $0.53, $0.06 better than the analyst estimate of $0.47. Revenue for the quarter came in at $152.4 million versus the consensus estimate of $138.63 million.
GUIDANCE:
Halozyme Therapeutics sees FY2022 EPS of $2.10-$2.25, versus the consensus of $2.23. Halozyme Therapeutics sees FY2022 revenue of $655-685 million, versus the consensus of $610.9 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Hasbro (HAS) brand strength sees earnings top expectations
- Farmers National Banc (FMNB) Tops Q1 EPS by 1c
- Blue Foundry Bancorp (BLFY) Tops Q1 EPS by 9c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
